Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06526741 · ClinicalTrials.gov registry record
ASF Alport Patient Registry
A clinical trial of Alport Syndrome and Thin Basement Membrane Disease, sponsored by Alport Syndrome Foundation.
- Recruiting
- Registry status
- 2,500
- Enrollment target
- 1
- Study location
NCT06526741 is a study of Alport Syndrome and Thin Basement Membrane Disease that is actively recruiting participants, run by Alport Syndrome Foundation. The registered enrollment target is 2,500 participants, above the 119-participant average among 5 other Alport Syndrome trials with a reported enrollment target (2001% higher). The trial reports 1 study location across 1 state.
The verdict
NCT06526741, a study of Alport Syndrome and Thin Basement Membrane Disease, is actively recruiting participants, sponsored by Alport Syndrome Foundation.
- RECRUITING
- Registry status
- 2,500 participants
- Enrollment target
- 1
- Study location
Study Summary
Alport Syndrome Foundation's (ASF's) Alport Patient Registry (the Registry) is open to individuals living with Alport syndrome in the United States (US) and US territories and outlying islands. The Registry welcomes participants of all ages who have a confirmed clinical diagnosis of Alport syndrome. A confirmed diagnosis could be obtained via genetic testing, biopsy, and/or from a medical professional's clinical assessment of the individual's symptoms and/or family history. Participants can have any form and stage of this disease to be eligible for inclusion in the Registry. Patient participation in the Registry is crucial to helping attract and advance research, understanding understudied aspects of the disease, and informing clinical trials that may lead to Alport syndrome therapies and/or a cure. The Registry is accessed through a secure, online application. Participants report their own health history in the Registry and are encouraged to update any changes, at most, every three months. The security of each participant's information is a top priority. Any detail that could identify an individual participant is kept confidential in the Registry and such data are de-identified to protect the participant's privacy. No electronic health records or social security numbers are requested by or connected to the Registry. A parent or legal guardian may consent to enroll a child/dren Alport patient(s) under the age of 18 years. An additional assent form is used for individuals ages 7-17. At age 18, participants will be required to re-consent as an adult if they choose to continue to participate in the Registry.
Conditions Studied
Interventions
- OTHER Longitudinal data collection
Study Locations (1)
Arizona
- On-line only: https://asfalportpatientregistry.healthie.net - Scottsdale
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,500 participants |
| Start Date | 2023-08-24 |
| Est. Completion | 2048-08-23 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06526741
The ClinicalTrials.gov registry entry for NCT06526741 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 2,500 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 119-participant average among 5 other Alport Syndrome trials with a reported enrollment target (2001% higher). The listed sponsor is Alport Syndrome Foundation, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Alport Syndrome appearing as the primary indexed condition, and to 1 intervention - of which Longitudinal data collection is the first listed.
NCT06526741 reports 1 study location spanning 1 distinct geographic area - top geographies include Arizona.
Frequently Asked Questions
What is clinical trial NCT06526741 about?
NCT06526741 is a clinical study titled "ASF Alport Patient Registry". Alport Syndrome Foundation's (ASF's) Alport Patient Registry (the Registry) is open to individuals living with Alport syndrome in the United States (US) and US territories and outlying islands. The Registry welcomes participants of all ages who have a confirmed clinical diagnosis of Alport syndrome....
What is the current status of trial NCT06526741?
This trial is currently recruiting. The enrollment target is 2,500 participants. The study started on 2023-08-24. Estimated completion is 2048-08-23.
What conditions does trial NCT06526741 study?
This clinical trial studies the following conditions: Alport Syndrome, Thin Basement Membrane Disease, Hereditary Nephritis.
What interventions are being tested in trial NCT06526741?
The interventions under investigation include: Longitudinal data collection (OTHER).
Who is sponsoring clinical trial NCT06526741?
This trial is sponsored by Alport Syndrome Foundation, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06526741 being conducted?
This trial has 1 study location across Arizona. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Alport Syndrome
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of Sparsentan Treatment in Pediatrics With Proteinuric Glomerular Diseases
RECRUITING · Phase 2
-
NEPTUNE Match Study
RECRUITING · NA
-
Atrasentan in Patients With Proteinuric Glomerular Diseases
ACTIVE NOT RECRUITING · Phase 2
-
A Prospective Study of Microalbuminuria in Untreated Boys With Alport Syndrome
COMPLETED
-
A Study of RG-012 in Subjects With Alport Syndrome
COMPLETED · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.